[BPTH] Bio-Path Holdings, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.3 Change: 0.06 (4.84%)
Ext. hours: Change: 0 (0%)

chart BPTH

Refresh chart

Strongest Trends Summary For BPTH

BPTH is in the long-term up 670% in 2 years and down -38% in 8 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Bio-Path Holdings, Inc., a biotechnology company, focuses on developing therapeutic products utilizing its proprietary liposomal delivery technology to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion in the United States. Its principal product is Liposomal Grb-2, which is in a Phase I study for blood cancers, as well as in preclinical studies for triple negative and inflammatory breast cancers. The company is also developing Liposomal Bcl-2, which is a liposome delivered antisense cancer drug for treating lymphoma, breast cancer, colon cancer, prostate cancer, and leukemia. It has license agreement with MD Anderson Cancer Center relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Houston, Texas.

Fundamental Ratios
Shares Outstanding EPS-0.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-7
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-37.83% ROE-39.54% ROI
Current Ratio21 Quick Ratio Long Term Debt/Equity Debt Ratio0.05
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities Cash From Operating Activities-1.41 M Gross Profit
Net Profit-1.37 M Operating Profit-1.38 M Total Assets14.25 M Total Current Assets12.94 M
Total Current Liabilities620 K Total Debt Total Liabilities620 K Total Revenue
Technical Data
High 52 week38.86 Low 52 week0.59 Last close15.53 Last change-7.34%
RSI37.9 Average true range1.33 Beta0.15 Volume147.73 K
Simple moving average 20 days-9.44% Simple moving average 50 days-21.41% Simple moving average 200 days80.59%
Performance Data
Performance Week-2.76% Performance Month-23.19% Performance Quart625.7% Performance Half80.62%
Performance Year802.91% Performance Year-to-date343.71% Volatility daily5.63% Volatility weekly12.58%
Volatility monthly25.79% Volatility yearly89.33% Relative Volume350.45% Average Volume3.9 M
New High New Low

News

2019-11-08 08:00:00 | Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

2019-10-29 06:47:29 | Investors Who Bought Bio-Path Holdings NASDAQ:BPTH Shares Five Years Ago Are Now Down 98%

2019-10-16 14:29:51 | Houston biotech co. avoids stock exchange delisting amid board shakeup

2019-10-15 08:00:00 | Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

2019-09-25 08:00:00 | Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

2019-09-14 09:36:24 | Is Bio-Path Holdings, Inc. NASDAQ:BPTH Excessively Paying Its CEO?

2019-09-03 16:01:00 | Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference

2019-08-26 07:00:00 | Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

2019-08-16 13:54:48 | Edited Transcript of BPTH earnings conference call or presentation 15-Aug-19 12:30pm GMT

2019-08-15 07:00:00 | Bio-Path Holdings Reports Second Quarter 2019 Financial Results

2019-08-08 16:01:00 | Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019

2019-07-17 11:39:47 | A Look At Benzinga Pro's Most-Searched Tickers For July 17, 2019

2019-07-16 08:18:13 | What Kind Of Shareholder Appears On The Bio-Path Holdings, Inc.'s NASDAQ:BPTH Shareholder Register?

2019-05-16 15:07:25 | Edited Transcript of BPTH earnings conference call or presentation 16-May-19 12:30pm GMT

2019-05-16 07:05:32 | Bio-Path: 1Q Earnings Snapshot

2019-05-16 07:00:00 | Bio-Path Holdings Reports First Quarter 2019 Financial Results

2019-05-16 06:30:00 | Bio-Path Holdings, Inc. to Host Earnings Call

2019-05-15 08:16:20 | Easy Come, Easy Go: How Bio-Path Holdings NASDAQ:BPTH Shareholders Torched 97% Of Their Cash

2019-05-10 16:01:00 | Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019

2019-04-29 09:00:00 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. NASDAQ: BPTH

2019-04-15 16:33:20 | How This Highly Rated Biotech Stock Added To Its Meteoric Run

2019-04-15 13:01:14 | Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

2019-04-15 10:46:00 | Bio-Path's stock rockets after withdrawal of stock offering

2019-04-03 08:00:00 | Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019

2019-03-21 06:13:08 | Should You Buy Bio-Path Stock After 5-Fold Gain? 3 Pros, 3 Cons

2019-03-20 09:15:01 | Bio-Path Holdings Reports Full Year 2018 Financial Results

2019-03-20 06:30:00 | Bio-Path Holdings, Inc. to Host Earnings Call

2019-03-15 16:01:00 | Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019

2019-03-14 15:10:00 | Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

2019-03-12 09:15:00 | Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

2019-03-08 13:25:18 | The Secret To Trading Stocks Like Bio-Path That Helped Me Quit My Desk Job And Make Thousands

2019-03-08 07:30:00 | The Device Market That Drove One Company From $2.50 to $65 Has a New Entrant

2019-03-07 11:55:50 | Traders Mystified by 3000% Surge in Shares of Cancer-Drug Maker

2019-03-07 10:35:00 | UPDATE: Bio-Path stock gains another 130% on Thursday

2019-03-06 14:35:00 | Bio-Path Holdings Updates Clinical Trial Data and it Sounds Promising

2019-03-06 14:30:00 | Bio-Path stock soars in active trade after announcing Phase 2 trial update

2019-03-06 13:27:11 | Bio-Path Holdings News: Why BPTH Stock Is Skyrocketing Today

2019-03-06 10:00:00 | Under the Radar Cannabis Stock-THC Therapeutics, Inc.

2019-03-06 08:00:00 | Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

2019-03-04 06:10:38 | Is Bio-Path Holdings, Inc.’s NASDAQ:BPTH CEO Pay Justified?

2019-02-28 08:00:00 | Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

2019-01-24 16:30:00 | Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. NASDAQ: BPTH

2019-01-23 16:01:00 | Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

2019-01-18 12:31:35 | Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

2019-01-18 08:00:00 | Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

2019-01-17 16:07:02 | Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

2019-01-16 08:24:33 | The Daily Biotech Pulse: Revance Common Stock Offering, Adcom Catalyst For Amgen

2019-01-14 22:23:31 | Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock

2019-01-14 16:01:00 | Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

2018-12-27 08:49:36 | Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook